Gastric Cancer Diagnostic Procedure Market Report 2026

The gastric cancer diagnostic procedure market size has grown strongly in recent years. It will grow from $1.54 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to use of endoscopy in gastric diagnosis, adoption of biopsy procedures, availability of imaging tests, hospital-based diagnostic infrastructure, development of pathology labs.

The gastric cancer diagnostic procedure market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growth in liquid biopsy techniques, expansion of molecular diagnostics, demand for early detection, automation in diagnostic workflows, AI-enabled imaging analysis. Major trends in the forecast period include growing use of endoscopic diagnostic techniques, rising adoption of molecular and genetic testing, increased demand for early-stage cancer detection, expansion of non-invasive diagnostic procedures, integration of advanced imaging technologies.

The increasing prevalence of smoking is expected to propel the growth of the gastric cancer diagnostic procedure market in the coming years. Smoking involves the inhalation and exhalation of smoke generated from burning tobacco or other substances. Gastric cancer diagnostic procedures are especially important for individuals with a history of smoking or those at elevated risk of smoking-related cancers, as they support early detection and identification of precancerous lesions, aid in the development of personalized and targeted treatment plans, improve care coordination, and enable comprehensive evaluation of the gastric mucosa and surrounding tissues. For example, in July 2023, according to data published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, tobacco use is responsible for more than 8 million deaths annually worldwide, including 1.3 million non-smokers exposed to second-hand smoke. Consequently, the growing prevalence of smoking is driving the expansion of the gastric cancer diagnostic procedure market.

Key players in the gastric cancer diagnostic procedure market are prioritizing technological innovation, including the development of dual cell-free and exosomal miRNA liquid biopsy assays, to strengthen their competitive positioning. These advanced assays detect small noncoding RNAs that circulate freely in the bloodstream as well as those encapsulated within tumor-derived exosomes, enabling highly sensitive and specific gastric cancer detection through a simple blood sample. For instance, in December 2024, Cizzle Bio, a U.S.-based biotechnology company, launched its DEX G2 blood test, which integrates cell-free and exosomal miRNA analysis to achieve approximately 95% sensitivity and 97% specificity, while requiring only a standard blood draw instead of invasive endoscopic procedures. This innovation supports earlier diagnosis and expanded screening potential, although broader adoption may be limited by regulatory approval processes and the need for real-world clinical validation.

In March 2023, Pfizer, a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aimed to strengthen its oncology portfolio by incorporating Seagen’s advanced antibody-drug conjugate (ADC) technology and broadening its range of innovative cancer treatments, reinforcing its leadership position in the oncology market. Seagen Inc. is a US-based biotechnology company focused on the discovery, development, and commercialization of transformative cancer therapies.

Major companies operating in the gastric cancer diagnostic procedure market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Myriad Genetics Inc., Foundation Medicine Inc., Biocept Inc., Illumina Inc., Roche Diagnostics, QIAGEN N V, Bio‑Rad Laboratories Inc., Siemens Healthineers, Danaher Corporation, Becton Dickinson, bioMérieux SA, PerkinElmer Inc., NeoGenomics Laboratories, Guardant Health Inc., Natera Inc., Caris Molecular Diagnostics, Adaptive Biotechnologies Corp, 10x Genomics Inc.

North America was the largest region in the gastric cancer diagnostics procedure market in 2025. The regions covered in the gastric cancer diagnostic procedure market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer diagnostic procedure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastric cancer diagnostic procedure market by increasing costs of imported diagnostic instruments, imaging systems, and molecular testing kits. Diagnostic centers and hospitals are most affected due to reliance on imported technologies. These tariffs increase diagnostic costs by raising expenses for endoscopic imaging, biopsy analysis, and molecular profiling, potentially delaying early detection. However, they support domestic manufacturing of diagnostic equipment, strengthening regional capabilities in cancer diagnostics.

The gastric cancer diagnostic procedure market research report is one of a series of new reports that provides gastric cancer diagnostic procedure market statistics, including gastric cancer diagnostic procedure industry global market size, regional shares, competitors with a gastric cancer diagnostic procedure market share, detailed gastric cancer diagnostic procedure market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer diagnostic procedure industry. This gastric cancer diagnostic procedure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastric cancer diagnostic procedures refer to techniques used for the identification and evaluation of cancerous cells that develop in the stomach. These procedures are employed to diagnose stomach cancer.

The main procedures involved in gastric cancer diagnosis include endoscopic procedures, biopsy, tissue tests, laboratory tests, in vitro diagnostic tests, imaging tests, molecular diagnostics, multiplex molecular diagnostics, immunoassays, and others. An endoscopic procedure involves examining an internal organ, such as the gastrointestinal tract, by inserting a long, thin tube into the body. Endoscopy is commonly used in gastric cancer diagnosis to detect stomach cancer. It is suitable for both symptomatic and asymptomatic cases and provides solutions in the form of instruments, reagents and consumables, and services. The body fluids required for these procedures include blood, urine, saliva, stomach juice, tissue, and others, to enable the detection and management of early-stage and advanced gastric cancer.

The gastric cancer diagnostics procedure market includes revenues earned by entities that provide diagnostic procedures such as surgery, chemotherapy, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.